Table 1.
Study design and baseline characteristics of the included patients.
| Author name and study date | Study design | Treatment group (number of patients) | Age mean (SD) | Sex female | CHA2DS VASc score Mean (SD) | Prior stroke or embolization | Heart failure | Hypertension | DM | Smoker |
|---|---|---|---|---|---|---|---|---|---|---|
| Pokorney et al. (10) | RCT | Apixaban (82) | 68.75 (4.3229) | 34 (41.5%) | 4.0 (0.6124) | 17 (20.7%) | N/A | N/A | N/A | N/A |
| Warfarin (72) | 67.25 (3.4611) | 22 (30.6%) | 4.0 (0.6124) | 12 (16.7%) | N/A | N/A | N/A | N/A | ||
| Siontis et al. (11) | Retrospective cohort study | Apixaban (2,351) | 68.87 (11.49) | 1,071 | 5.27 (1.77) | 778 (33.1) | 1,868 (79.5) | 2,342 (99.6) | 1,773 (75.4) | 978 (41.6) |
| Warfarin (23,172) | 68.15 (11.93) | 10,600 | 5.24 (1.79) | 7,683 (33.2) | 17,959 (77.5) | 23,079 (99.6) | 17,348 (74.9) | 8,819 (38.1) | ||
| Chan et al. (12) | Retrospective cohort study | Rivaroxaban (244) | 66.9 (12) | 96 | 2.2 (1.0) | 14.6% (36) | 14.1% (34) | 84.9% (207) | 67.8% (165) | N/A |
| Warfarin (8,064) | 70.6 (11) | 3,129 | 2.4 (1.0) | 12.0% (968) | 20.8% (1,677) | 88.5% (7,137) | 67.9% (5,475) | N/A | ||
| Dabigatran (281) | 68.4 (12) | 115 | 2.3 (1.0) | 11.2% (31) | 14.6% (41) | 86.9% (244) | 70.4% (198) | N/A | ||
| Sarratt et al. (13) | Retrospective, cohort study | Apixaban (40) | 70.9 (5.25) | 20 (50.0) | 4.25 (1.4361) | 6 (15.0%) | 19 (47.5 | 33 (82.5) | 22 (55.0 | N/A |
| Warfarin (120) | 66.5 (6.75) | 42(51.7) | 4.75 (1.4216) | 29 (24.2%) | 60 (50.0) | 97 (80.8) | 59 (49.2) | N/A | ||
| De Vriese et al. (14) | RCT | Rivaroxaban (46) | 79.525 (2.731) | 11 (23.9%) | 4.7 (1.4) | 15 (32.6 %) | 17 (37%) | N/A | 20 (43.5 %) | N/A |
| Warfarin (44) | 79.1 (3.6894) | 19 (43.13%) | 4.8 (1.5) | 16 (36.4%) | 9(20.5%) | N/A | 20 (45.5 %) | N/A |
SD, Standard deviation.